Daniel Catenacci
@DocCatenacci
Followers
3K
Following
3K
Media
236
Statuses
2K
Medical Oncologist. "Targeted therapies for targeted populations”
Chicago, IL
Joined June 2014
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
5
27
108
#CM577 .If only we could have known years ago, maybe we could’ve spared all those patients ineffective (worse than nothing?), toxic expensive therapy.
#CM577 there is no benefit (especially CPS0) in CPS low/neg tumors. 44% of pts. And this is not even by histology which would make adenocarcinoma look even worse. Why is this buried in the supplement? & Why would you give this drug for a year to people having no benefit?.
1
5
15
@LizzySmyth1 HR 0.78 NS per the presentation but not in the paper (rather HR 0.99 <12m HR 0.67) >12m) . Where have we seen this tuning fork curve before? ~1/3 pts no diff. CM577. I think it’s a good idea to see the results by PDL1 1, 5, 10: will likely show same thing as all previous studies
0
4
10
Better late than never, I guess.
📢 FDA ODAC gets it ✅️ for patients. Immune checkpoint inhibitors are a PD-L1 targeted 🎯 therapy in GEA. No target, no efficacy. Let's focus on: . ➡️ alternative targets (CLD 18.2, FGFR2b, MTAP. ).➡️ overcoming immune evasion (bispecifics, T-cell engagers, CAR-T. ).
1
1
8
RT @KrishanJethwa: 🚨PRODIGE23🚨. Long term results now published!.T3-4 rectal adenocarcinoma.Randomized:.CRT➡️🔪➡️FOLFOX.mFOLFIRINOX ➡️ CRT➡️….
0
100
0
Already Approved in Japan 3/26/24. Different manufacturing sites for the two countries hopefully??.
0
0
4
#SPOTLIGHT #GLOW #Zolbetuximab #Vyloy. "Zolbetuximab BLA resubmitted 5/9/2024, after CRL issued on 1/4/2024 by FDA due to 3rd-party manufacturer deficiencies seen during the pre-license inspection of the facility." Target Action Date: 11/9/2024.
1
1
10
Thank you for this very pivotal study to streamline perioperative therapy for esophageal and gastroesophageal junction adenocarcinoma. #ESOPEC.
🔥 ASCO 2024 Plenary: Prof Dr @JDekervel (UZ Leuven) and Prof Dr @FlorianLordick (University of Leipzig) discuss the ESOPEC trial, comparing FLOT perioperative chemotherapy with neoadjuvant chemoradiotherapy for adenocarcinoma of the oesophagus or oesophagogastric junction.
0
1
10
RT @Medi_Mix: 🔥 ASCO 2024 Plenary: Prof Dr @JDekervel (UZ Leuven) and Prof Dr @FlorianLordick (University of Leipzig) discuss the ESOPEC tr….
0
3
0
RT @DocCatenacci: @mmeatock Yes research warranted, not SOC. Control here arm did very well compared to overt stage IV disease, as expected….
0
1
0
IKF-575/#RENAISSANCE phase III. Addressing #oligometastatic #GEA more aggressively, my heart said yes, but my brain said no:
0
3
11
RT @DocCatenacci: @ILSONDavid @RenoHemonc I guess we must agree to disagree until we see prospective phase 3 data. Thankfully others have a….
0
1
0
RT @DocCatenacci: @ILSONDavid @RenoHemonc Do you call the benefit of CROSS over surgery alone ‘modest’ with a HR of 0.75? FLOT had HR of 0.….
0
2
0
RT @DocCatenacci: Unfair comparison of ITT R0 in FLOT vs R0 of those going to surgery in CROSS. Also,Why compare surrogate endpnts of OS wh….
0
1
0
0
5
0
RT @DocCatenacci: #justmath.I particularly like the comment that this is homework for 9-yr olds. @GermanBiotech .CROSS-trial comparisons r….
0
4
0
RT @DocCatenacci: Hey #medtwitter, I need some help with the math on this one:.@OncoAlert . If B - A = X.& C - A = X.& B=C.& D - B = X.& D….
0
2
0
RT @DocCatenacci: @NiuSanford @SuyogCancer Last, I would say that ~90% of pts will have a PET response w FLOT, & we saw this also w FOLFIRI….
0
1
0
RT @DocCatenacci: @NiuSanford @SuyogCancer Tweet 6/6:.From tweet 5/6, if we have a prospective study that seeks organ preservation, documen….
0
1
0